Harvard professor gets central role in REMEDY
This week it became formally clear that Daniel H. Solomon, professor at Harvard Medical School (Boston, USA) will be an official visiting professor at the research center REMEDY.
- This is a fantastic strength for REMEDY and Diakonhjemmet hospital, says Espen A. Haavardsholm, center director at REMEDY and head of research and innovation at the hospital.
In addition to his role at Harvard, Solomon is head of the Section of Clinical Sciences in rheumatology at Brigham and Women's Hospital, where he is also employed by the Division of Pharmacoepidemiology and Pharmacoeconomics. The focus of his research is, among other things, clinical studies, health service research, treatment quality and pharmacoepidemiology within rheumatic diseases and osteoporosis. He is editor-in-chief of the renowned journal Arthritis and Rheumatology.
- The fact that such international capacity is part of our professional environment provides unique opportunities to discuss new projects and results. We have collaborated with Dan Solomon for many years, and are happy that the collaboration is now being developed further. Among other things, Solomon will be present at the Diakonhjemmet for a week in March, where he will give an open lecture, participate in a research seminar, and contribute to a number of activities especially aimed at younger researchers, says Haavardsholm.
Siri Lillegraven, deputy director at REMEDY and head of the Clinical Research Unit, previously worked for two years in Solomon's research group in Boston, USA. She says that he has a broad academic interest, which is reflected in the fact that he has been central to a large number of important studies and has an extensive publication list, with over 800 scientific articles. At the same time, Solomon is particularly known for being a good mentor to younger researchers, and has received several awards in recognition of this.
Initially, Solmon is associated with REMEDY as a visiting professor for one year, with the possibility of an extension for another year. The visiting professorship is formally affiliated with the Department of Clinical Medicine at the University of Oslo, which is also a partner in REMEDY.
